End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure
Retrieved on:
Wednesday, March 15, 2023
Other Manufacturing, Medical Supplies, Hospitals, Transport, Manufacturing, Practice Management, General Health, Pharmaceutical, Health, Logistics, Supply Chain Management, Oklahoma Hospital Association, Risk, Dimercaprol, Hyperparathyroidism, Supraventricular tachycardia, ASHP, Patient, EDSA, Calcitriol, Organic acid, Knowledge, Akorn, Physostigmine, East End Drugs, Bankruptcy, Adenosine, CHA, Anticholinergic, Mayo Clinic, Kidney, Pharmaceutical industry, Risk management, Medical device, Nursing, Vizient, Inc.
The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
Key Points:
- The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
- “Transparency regarding drug shortages is important to ensure patient care remains uninterrupted,” said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member.
- Clinicians and providers, to exercise a stewardship mindset and review purchasing and formulary status to determine conservation and mitigation strategies.
- “Advance knowledge of supply disruptions is part of the transparency that the End Drug Shortages Alliance has advocated for since forming.